Vanda Pharmaceuticals Inc.
General ticker "VNDA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $383.4M (TTM average)
Vanda Pharmaceuticals Inc. does not follow the US Stock Market performance with the rate: -17.3%.
Estimated limits based on current volatility of 3.1%: low 4.08$, high 4.34$
Factors to consider:
- Total employees count: 533 (+44.8%) as of 2025
- Countries other than US accounted for 5.0% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Dependence on product success, FDA safety and review issues, Regulatory and compliance, Third-party risks, Economic downturns and volatility
- Current price 13.7% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.67$, 9.70$]
- 2026-12-31 to 2027-12-31 estimated range: [3.93$, 8.41$]
Financial Metrics affecting the VNDA estimates:
- Negative: with PPE of -1.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0
- Negative: 58.56 < Shareholder equity ratio, % of 66.92 <= 69.38
- Positive: Investing cash flow per share per price, % of 22.15 > 2.08
Short-term VNDA quotes
Long-term VNDA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $192.64MM | $198.77MM | $216.10MM |
| Operating Expenses | $206.59MM | $239.43MM | $367.27MM |
| Operating Income | $-13.95MM | $-40.66MM | $-151.17MM |
| Non-Operating Income | $20.29MM | $17.74MM | $12.52MM |
| R&D Expense | $76.82MM | $74.43MM | $109.27MM |
| Income(Loss) | $6.34MM | $-22.92MM | $-138.65MM |
| Taxes | $3.83MM | $-4.02MM | $81.83MM |
| Net Income(Loss)* | $2.51MM | $-18.90MM | $-220.47MM |
| Stockholders Equity | $544.91MM | $538.55MM | $327.19MM |
| Inventory | $1.36MM | $1.73MM | $1.85MM |
| Assets | $648.44MM | $656.20MM | $488.95MM |
| Operating Cash Flow | $12.80MM | $-15.76MM | $-109.44MM |
| Capital expenditure | $0.38MM | $0.49MM | $1.00MM |
| Investing Cash Flow | $-12.06MM | $-17.43MM | $94.86MM |
| Financing Cash Flow | $0.00MM | $-0.15MM | $-2.91MM |
| Earnings Per Share** | $0.04 | $-0.33 | $-3.74 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.